scholarly journals Beneficial Acute Effects of Rho-Kinase Inhibitor in Patients With Pulmonary Arterial Hypertension

2006 ◽  
Vol 70 (2) ◽  
pp. 174-178 ◽  
Author(s):  
Ken Ishikura ◽  
Norikazu Yamada ◽  
Masaaki Ito ◽  
Satoshi Ota ◽  
Mashio Nakamura ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Kinase Inhibitor ◽  
Rho Kinase ◽  
Acute Effects ◽  
Rho Kinase Inhibitor ◽  
Pulmonary Arterial

scholarly journals Double-Blind, Placebo-Controlled Clinical Trial With a Rho-Kinase Inhibitor in Pulmonary Arterial Hypertension

2013 ◽  
Vol 77 (10) ◽  
pp. 2619-2625 ◽  
Author(s):  
Yoshihiro Fukumoto ◽  
Norikazu Yamada ◽  
Hiromi Matsubara ◽  
Minori Mizoguchi ◽  
Kazuaki Uchino ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Kinase Inhibitor ◽  
Rho Kinase ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Rho Kinase Inhibitor ◽  
Pulmonary Arterial

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension

2010 ◽  
Vol 25 (2) ◽  
pp. 144-149 ◽  
Author(s):  
Hiroshi Fujita ◽  
Yoshihiro Fukumoto ◽  
Kenya Saji ◽  
Koichiro Sugimura ◽  
Jun Demachi ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Kinase Inhibitor ◽  
Rho Kinase ◽  
Rho Kinase Inhibitor ◽  
Pulmonary Arterial

Acute effects of inhaled iloprost on intracardiac conduction in patients with pulmonary arterial hypertension

Herz ◽  
2021 ◽  
Author(s):  
Mustafa Yildiz ◽  
Serkan Kahraman ◽  
Ozgur Surgit ◽  
Hicaz Zencirkiran Agus ◽  
Begum Uygur ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Acute Effects ◽  
Inhaled Iloprost ◽  
Pulmonary Arterial

Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib

2019 ◽  
Vol 26 (3) ◽  
pp. 738-741 ◽  
Author(s):  
Senem Maral ◽  
Sule Mine Bakanay ◽  
Orhan Kucuksahin ◽  
Imdat Dilek
Keyword(s):  
Adverse Event ◽  
Pulmonary Arterial Hypertension ◽  
Pleural Effusion ◽  
Chronic Myeloid Leukemia ◽  
Pericardial Effusion ◽  
Arterial Hypertension ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Pulmonary Arterial ◽  
Dasatinib Treatment

Introduction Dasatinib is a potent tyrosine-kinase inhibitor which is used for chronic myeloid leukemia treatment. Pleural effusion is a frequent side effect in patients during dasatinib treatment. Pulmonary arterial hypertension is a rare and life-threatening adverse event of dasatinib. The relationship between dasatinib and autoimmune disorders is unclear, but there are reports of possible mechanisms that have triggered autoimmunity by dasatinib. Case report A 53-year-old male was diagnosed with chronic myeloid leukemia and initiated imatinib mesylate as a treatment. Imatinib was changed to dasatinib as the patient was unresponsive in the first year of treatment. In the fourth year of dasatinib when chronic myeloid leukemia was in both hematological and cytogenetical remission, the patient presented with bilateral massive exudative pleural effusion. Echocardiography was consistent with pericardial effusion with right ventricle enlargement and normal left-side cardiac function. Pulmonary arterial hypertension was diagnosed with high systolic pulmonary arterial pressure. When he had fever and arthralgia, further investigation showed positivity of anti-nuclear antibodies (1/160 titer) and anti-RNP/Sm, which have high specificity for the diagnosis of Systemic Lupus Erythematosus (SLE). Management and outcome Dasatinib was discontinued and nilotinib was initiated. As the pleural effusion persisted despite diuretics and methylprednisolone, mycophenolate mofetil was initiated as a steroid-sparing immune-suppressive agent. The lupus-like symptoms disappeared, and antibodies became undetectable after dasatinib discontinuation. Pericardial effusion improved and pleural effusion did not relapse. Discussion Screening for auto-antibodies may be recommended for patients with a history or symptoms of autoimmune disease before starting dasatinib. All patients who develop pleural effusion while on dasatinib treatment should be investigated for antibodies for lupus.

Sign in / Sign up

Export Citation Format

Share Document